FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Press/Media

Period12 Feb 2021 → 13 Feb 2021

Media coverage

29

Media coverage